GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd (SHSE:688336) » Definitions » Net Issuance of Preferred Stock

Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Net Issuance of Preferred Stock : ¥0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Sunshine Guojian Pharmaceutical (Shanghai) Co Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Sunshine Guojian Pharmaceutical (Shanghai) Co's net issuance of preferred for the three months ended in Mar. 2025 was ¥0 Mil. The number is 0, which means that Sunshine Guojian Pharmaceutical (Shanghai) Co has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Sunshine Guojian Pharmaceutical (Shanghai) Co's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2025 was ¥0 Mil.


Sunshine Guojian Pharmaceutical (Shanghai) Co Net Issuance of Preferred Stock Historical Data

The historical data trend for Sunshine Guojian Pharmaceutical (Shanghai) Co's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Guojian Pharmaceutical (Shanghai) Co Net Issuance of Preferred Stock Chart

Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
Trend Dec12 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sunshine Guojian Pharmaceutical (Shanghai) Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sunshine Guojian Pharmaceutical (Shanghai) Co Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunshine Guojian Pharmaceutical (Shanghai) Co Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Sunshine Guojian Pharmaceutical (Shanghai) Co's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description

Traded in Other Exchanges
N/A
Address
No.399 Libing Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
Executives
Weng Zhi Bing Core technical personnel
Huang Hao Min Core technical personnel

Sunshine Guojian Pharmaceutical (Shanghai) Co Headlines

No Headlines